June 18 | 2024

2CUREX APPOINTS OLE THASTRUP AS NEW CEO

Read more
June 18 | 2024

Correction: 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

Read more
June 17 | 2024

2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

Read more
May 29 | 2024

NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (PUBL)

Read more
May 29 | 2024

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (PUBL)

Read more
May 29 | 2024

Correction: Revised Financial Calendar Announcement

Read more
May 29 | 2024

Correction: Revised Financial Calendar Announcement

Read more
May 27 | 2024

Revised Financial Calendar Announcement

Read more
May 7 | 2024

2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE

Read more
March 16 | 2024

2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS

Read more
February 29 | 2024

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Read more
February 29 | 2024

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

Read more
February 22 | 2024

2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024

Read more
February 12 | 2024

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)

Read more
February 12 | 2024

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBL)

Read more
January 4 | 2024

2cureX announces changes to the Board of Directors.

Read more
December 29 | 2023

2cureX announces changes to the management

Read more
December 6 | 2023

2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial

Read more